Association of pegylated liposomal doxorubicin and ifosfamide in early recurrent ovarian cancer patients: A Multicenter Phase II Trial-Reference-Cited by-同舟云学术

Association of pegylated liposomal doxorubicin and ifosfamide in early recurrent ovarian cancer patients: A Multicenter Phase II Trial

Published:2010-03 Issue:3 Volume:116 Page:312-316
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Joly Florence,Sevin Emmanuel,Lortholary Alain,Priou Frank,Paitel J.F.,Fabbro Michel,Henry-Amar Michel,Hamond Karim,Bourgeois Hugues

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,Oncology

Reference45 articles.

1. Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis;Harries;Lancet Oncol.,2002

2. Systemic therapy for ovarian cancer: current status and new treatments;Ozols;Semin. Oncol.,2006

3. 2004 Consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004);du;Ann. Oncol.,2005

4. Future options for first-line therapy of advanced ovarian cancer;du;Int. J. Gynecol. Cancer,2005

5. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results;Piccart;J. Natl. Cancer Inst.,2000

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Salvage chemotherapy with docetaxel and pegylated liposomal doxorubicin in pretreated patients with platinum- and taxane-sensitive ovarian cancer: a multicenter phase II trial of the Hellenic Oncology Research Group (HORG);Cancer Chemotherapy and Pharmacology;2014-02-15

2. Phase II study of ifosfamide and cisplatin for the treatment of recurrent ovarian cancer;Cancer Chemotherapy and Pharmacology;2013-08-03

3. Clinical Trials with Pegylated Liposomal Doxorubicin in the Treatment of Ovarian Cancer;Journal of Drug Delivery;2013-03-14

4. Pharmacokinetic and toxicity considerations for the use of anthracyclines in ovarian cancer treatment;Expert Opinion on Drug Metabolism & Toxicology;2011-03-24